Work

Abstract CT244: Trial in progress: Phase 1/2 study of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced solid tumors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct244

Authors: Alexander N. Shoushtari, Adam J. Schoenfeld, Kai He, Jason A. Chesney, Juan Carlos Varela, Justin T. Moyers, Gino K. In, Yazan Samhouri, Rodabe N. Amaria, Parameswaran Hari, Giridharan Ramsingh, Camille Renard, Prakash Prabhakar, Lauren Mclaughlin, Mercay Reuter, Allison Betof Warner

Institutions: Memorial Sloan Kettering Cancer Center, The Ohio State University, Orlando Health, Angeles Clinic and Research Institute, University of Southern California, Allegheny Health Network, The University of Texas MD Anderson Cancer Center, Stanford Medicine, Stanford University

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409821728

Cites:

Cited by: 1

Related to: 10